e-learning
resources
Amsterdam 2015
Wednesday, 30.09.2015
Pulmonary hypertension: new treatment insights
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models
Denielli Bos (Amsterdam, Netherlands), Denielli Da Silva Goncalves Bos, Chris Happé, Ingrid Schalij, Wioletta Pijacka, Julian F. Paton, Harm-Jan Bogaard, Nico Westerhof, Albertus C. Van Rossum, Anton Vonk-Noordegraaf, Frances S. De Man, M. Louis Handoko
Source:
International Congress 2015 – Pulmonary hypertension: new treatment insights
Session:
Pulmonary hypertension: new treatment insights
Session type:
Oral Presentation
Number:
4997
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Denielli Bos (Amsterdam, Netherlands), Denielli Da Silva Goncalves Bos, Chris Happé, Ingrid Schalij, Wioletta Pijacka, Julian F. Paton, Harm-Jan Bogaard, Nico Westerhof, Albertus C. Van Rossum, Anton Vonk-Noordegraaf, Frances S. De Man, M. Louis Handoko. Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models. Eur Respir J 2015; 46: Suppl. 59, 4997
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Formation of typical vascular lesions in a new experimental model of pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Role of survivin in experimental models of pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
Erythropoietin recapitulates hemodynamic features of hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Repeated embolization and fibrinolysis inhibition induce chronic thromboembolic pulmonary hypertension in rabbits
Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers
Year: 2013
Therapeutic potential of DMHCA for pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Intact serotonin signaling is not required for the development of severe angioproliferative pulmonary hypertension in rats
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014
Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Pulmonary vascular reactivity in pulmonary hypertension due to left heart disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Siah2 in pulmonary hypertension and right ventricular hypertrophy
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Chronic thromboembolic pulmonary hypertension: animal models
Source: Eur Respir J 2013; 41: 1200-1206
Year: 2013
Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models
Source: Eur Respir J, 57 (5) 2003271; 10.1183/13993003.03271-2020
Year: 2021
Peripheral arterial stiffness and endothelial dysfunction in pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load
Year: 2015
Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept